Advancing Precision Medicine in High-Risk Breast Cancer: BRCA Mutations, Triple-Negative, and HR+/HER2– Subtypes - Episode 1

NATALEE and monarchE: Clinical Data Review and Insights Into Treating High-Risk HR+/HER2_ Early-Stage Breast Cancer

,

Panelists discuss the recent data from the NATALEE and monarchE studies, focusing on adjuvant CDK4/6 inhibitor selection for high-risk HR-positive/HER2-negative (HR+/HER2–) early breast cancer patients, and explore how to interpret the different efficacy signals, particularly the early curve separation observed in monarchE versus NATALEE.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: NATALEE and monarchE: Clinical Data Review and Insights Into Treating High-Risk HR+/HER2_ Early-Stage Breast Cancer
    EP. 2: Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data
    EP. 3: BRCA Testing in Early-Stage and Metastatic Breast Cancer
    EP. 4: OlympiA: Data Updates From SABCS 2024
    EP. 5: Role of PARP Inhibitors in Somatic BRCA Mutations and Data Update for PARP Inhibitors
    EP. 6: KN-522: Clinical Implications and Insights Into Clinical Practice
    EP. 7: Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC
    EP. 8: SABCS 2024: Promising Studies in HR+ and HER2– mBC and Early-Stage TNBC

    Video content above is prompted by the following:

    • Based on the monarchE and NATALEE trials, how do you approach adjuvant CDK4/6 inhibitor selection for patients with high-risk HR+/HER2– early breast cancer?
    • How do you weigh the different efficacy signals between the trials, particularly the early separation of curves in monarchE versus NATALEE?
    x